Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
about
High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudySmall heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDLA Review of Currently Available Fenofibrate and Fenofibric Acid FormulationsA comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study.Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects.Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice.Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated statesAssociation of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome statusThe dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic miceFenofibrate: treatment of hyperlipidemia and beyond.The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Fenofibrate and metabolic syndrome.Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics.Fenofibrate in the treatment of dyslipidemia associated with HIV infection.AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.Fenofibrate and the kidney: an overview.Carotid intima-media thickness testing as an asymptomatic cardiovascular disease identifier and method for making therapeutic decisions.Summarizing the FIELD study: lessons from a 'negative' trial.Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicPathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα.Serum uric acid: marker for atherosclerosis as it is positively associated with "atherogenic index of plasma".Effect of Fenofibrate Medication on Renal Function.The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVCPleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.Optimization and evaluation of lyophilized fenofibrate nanoparticles with enhanced oral bioavailability and efficacy.Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway.Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers.
P2860
Q28476672-697182CF-261D-4491-9945-BEF1C1641639Q28488385-15E4501A-C96B-4ED9-BD28-FF7CEF660910Q28538861-B7B42917-9489-4A12-A143-B6D519EBC304Q30048180-3590F48D-7F38-409B-A0A5-36E2B0B05041Q30387831-DA8F5ED8-6491-458E-B969-1E2A90C026DCQ33577851-AF49605D-35F0-4B68-831F-1BF5E83A6B12Q33940875-7AD69ED5-B9D5-43F8-B2C3-4A5897C15718Q34188082-421AEF48-482E-4226-BE71-032086593D97Q34347027-38142894-6944-4E33-9D4E-48F70C8C8440Q34662589-21C30A31-74B8-44F7-86A9-35FD486B4E42Q34670737-3F3BF0F0-0E04-4FA5-B81F-FADC0965AF3CQ35025924-8A53BDBD-063A-4A67-B552-8606C9E2FB24Q35115268-2517A440-24A4-44E9-B246-17790E0AE749Q35453774-65CB6D6F-D10E-4902-A67C-BDB3840C24D0Q36847314-2CA4B10D-1A29-430A-AF28-93AC22AD9649Q37019924-B37308CF-CA39-4C8A-A20A-BB566489AC38Q37109483-107648A1-5FDA-46DF-A154-5D0A475A90FFQ37183071-B5938F7C-8597-4DD3-9AF4-1470B1837656Q37230691-D7560E16-6E85-4494-AE2C-C35074F75FE3Q37329141-366C60AB-8AD3-41BF-9162-8F39665E0EFAQ37362674-2D61DE1D-672D-4C25-86A7-46BEF748E012Q37612824-32EF8E06-12FC-4D60-9818-A77102391556Q37645663-8AFEFEAE-5FEA-4548-92C9-7014F8DBCFF2Q37770249-6E13E313-EEFE-4697-B7ED-943F6176CFABQ37851958-4964690C-699B-4B76-A3F0-16F26D95018EQ37981958-A868D6F3-52BE-49A9-B9F1-EC90D8359819Q38042090-A5AA27E1-3B27-4D00-8513-673B13599A03Q38088377-E5A9C4EC-96CD-4F74-9C08-ED2D520AA0BBQ38118481-488F51DF-FA7B-4CDB-9A1D-EA92A250D238Q38160901-B61462B5-EFEF-400A-BFAE-D60C60A8B0FDQ38382774-B417231D-5B47-4C98-84E7-6D45C03C1C39Q38713219-9BEA8538-403E-4B4D-A1EF-22C98F9329E3Q39533790-9F5D0100-D113-462D-804B-5E54F47C3643Q41223740-EEA5063D-61BF-4A9C-B2CF-3E29D4B6E01BQ41948835-5954DB5D-B9F6-4BE6-9A36-A2FE3E98A031Q42164828-A57B2A11-381E-444D-B1D2-98686F24C813Q42586832-567D9F28-626B-4CE6-A759-9A5E8B4EC59AQ46533295-DF6C2EAC-FD76-4A91-A81E-ED1CFFFDFE3BQ47135495-556C1240-894D-4AD7-9A96-43002E167624Q47388747-EFD41BA5-73D3-4736-BA91-7D9E9D3ABE44
P2860
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@ast
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@en
type
label
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@ast
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@en
prefLabel
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@ast
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@en
P2860
P921
P1433
P1476
Fenofibrate: a review of its u ...... and type 2 diabetes mellitus.
@en
P2093
Katherine F Croom
P2860
P304
P356
10.2165/00003495-200767010-00013
P577
2007-01-01T00:00:00Z
P6179
1004708025